A 12-Week Randomized, Open-Label, Active Comparator Period Followed by a 12-Week Safety Extension Period to Evaluate the Safety and Efficacy of Fesoterodine in Subjects Aged 6 to 16 Years and > 25 KG with Symptoms of Detrusor Overactivity Associated with

  • Ziada, Ali (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date6/21/1210/31/14